35 results on '"Rocci, Alberto"'
Search Results
2. MM-372 A Phase III, Two-Stage, Randomized Study of Mezigdomide, Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
3. RWD-derived response in multiple myeloma
4. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
5. Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers
6. Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial
7. Retraction Notice to: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development
8. IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide‐dexamethasone therapy in multiple myeloma
9. Assessment of Associations between Derived Response and Overall Survival in Patients with Multiple Myeloma Using a US-Based Electronic Health Records Database
10. Lab-Based Response Assessment Algorithm Recapitulates Investigator's Response Assessment in the Phase 3 Bellini Trial
11. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
12. MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages
13. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial
14. Evaluating Suspected Cardiac Amyloidosis
15. Minimal residual disease by flow cytometry and allelic‐specific oligonucleotide real‐time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis
16. Venous thromboembolism in multiple myeloma – choice of prophylaxis, role of direct oral anticoagulants and special considerations
17. TOURMALINE-MM1: new oral triplet combination for patients with relapsed/refractory multiple myeloma
18. High IKAROS Expression in Bone Marrow Environmental, But Not in Myeloma Cells Predicts for Survival with Lenalidomide-Dexamethasone Therapy in Myeloma
19. Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
20. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis
21. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.
22. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
23. RETRACTED: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development
24. Proteomic Characterization of Circulating Extracellular Vesicles Identifies Novel Serum Myeloma Associated Markers
25. Small RNA Deep Sequencing Highlights the Important Contribution of Mirnas in Regulating IRF4/c-Myc Axis in Myeloma Development
26. A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.
27. MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?
28. Proteomic Characterization of the Multiple Myeloma Bone Marrow Extracellular Matrix
29. In Multiple Myeloma, Minimal Residual Disease (MRD) Is an Early Predictor of Progression and Is Modulated By Maintenance Therapy with Lenalidomide
30. Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors
31. Abstract 4855: Proteomic characterization of the extracellular matrix in multiple myeloma
32. The potential of miRNAs as biomarkers for multiple myeloma.
33. Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development.
34. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis
35. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.